Your browser doesn't support javascript.
loading
Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).
Pott, Henrique; Andrew, Melissa K; Shaffelburg, Zachary; Nichols, Michaela K; Ye, Lingyun; ElSherif, May; Hatchette, Todd F; LeBlanc, Jason; Ambrose, Ardith; Boivin, Guy; Bowie, William; Johnstone, Jennie; Katz, Kevin; Lagacé-Wiens, Phillipe; Loeb, Mark; McCarthy, Anne; McGeer, Allison; Poirier, Andre; Powis, Jeff; Richardson, David; Semret, Makeda; Smith, Stephanie; Smyth, Daniel; Stiver, Grant; Trottier, Sylvie; Valiquette, Louis; Webster, Duncan; McNeil, Shelly A.
Affiliation
  • Pott H; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada; Department of Medicine, Universidade Federal de São Carlos, São Carlos, Brazil.
  • Andrew MK; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada; Department of Medicine, Dalhousie University, Halifax, Canada.
  • Shaffelburg Z; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada; Department of Medicine, Dalhousie University, Halifax, Canada.
  • Nichols MK; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada; Public Health Agency of Canada, Halifax, Canada.
  • Ye L; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada.
  • ElSherif M; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada.
  • Hatchette TF; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada; Department of Medicine, Dalhousie University, Halifax, Canada.
  • LeBlanc J; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada; Department of Pathology, Dalhousie University, Halifax, Canada.
  • Ambrose A; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada.
  • Boivin G; CHU de Québec-Université Laval, Québec, Québec.
  • Bowie W; University of British Columbia, Vancouver, British Columbia, Canada.
  • Johnstone J; McMaster University, Hamilton, Ontario, Canada.
  • Katz K; North York General Hospital, Toronto, Ontario, Canada.
  • Lagacé-Wiens P; St. Boniface Hospital, Winnipeg, Manitoba, Canada.
  • Loeb M; McMaster University, Hamilton, Ontario, Canada.
  • McCarthy A; The Ottawa Hospital, Ottawa, Ontario, Canada.
  • McGeer A; Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Poirier A; Centre Intégré Universitaire de santé et services sociaux, Quebec, Quebec, Canada.
  • Powis J; Michael Garron Hospital, Toronto, Ontario, Canada.
  • Richardson D; William Osler Health System, Brampton, Ontario, Canada.
  • Semret M; McGill University, Montreal, Québec, Canada.
  • Smith S; University of Alberta Hospital, Edmonton, Alberta, Canada.
  • Smyth D; The Moncton Hospital, Moncton, New Brunswick, Canada.
  • Stiver G; University of British Columbia, Vancouver, British Columbia, Canada.
  • Trottier S; Centre Hospitalier Universitaire de Québec, Québec, Québec, Canada.
  • Valiquette L; Université de Sherbrooke, Sherbrooke, Québec, Canada.
  • Webster D; Horizon Health, Saint John, New Brunswick, Canada.
  • McNeil SA; Canadian Centre for Vaccinology, Dalhousie University, Halifax, Canada; Department of Medicine, Dalhousie University, Halifax, Canada. Electronic address: Shelly.McNeil@nshealth.ca.
Vaccine ; 41(42): 6359-6365, 2023 10 06.
Article in En | MEDLINE | ID: mdl-37696717
ABSTRACT

BACKGROUND:

Influenza vaccines prevent influenza-related morbidity and mortality; however, suboptimal vaccine effectiveness (VE) of non-adjuvanted trivalent inactivated influenza vaccine (naTIV) or quadrivalent formulations in older adults prompted the use of enhanced products such as adjuvanted TIV (aTIV). Here, the VE of aTIV is compared to naTIV for preventing influenza-associated hospitalization among older adults.

METHODS:

A test-negative design study was used with pooled data from the 2012 to 2015 influenza seasons. An inverse probability of treatment (IPT)-weighted logistic regression estimated the Odds Ratio (OR) for laboratory-confirmed influenza-associated hospitalization. VE was calculated as (1-OR)*100% with accompanying 95% confidence intervals (CI).

RESULTS:

Of 7,101 adults aged ≥ 65, 3,364 received naTIV and 526 received aTIV. The overall VE against influenza hospitalization was 45.9% (95% CI 40.2%-51.1%) for naTIV and 53.5% (42.8%-62.3%) for aTIV. No statistically significant differences in VE were found between aTIV and naTIV by age group or influenza season, though a trend favoring aTIV over naTIV was noted. Frailty may have impacted VE in aTIV recipients compared to those receiving naTIV, according to an exploratory analysis; VE adjusted by frailty was 59.1% (49.6%-66.8%) for aTIV and 44.8% (39.1%-50.0%) for naTIV. The overall relative VE of aTIV to naTIV against laboratory-confirmed influenza hospital admission was 25% (OR 0.75; 0.61-0.92), demonstrating statistically significant benefit favoring aTIV.

CONCLUSIONS:

Adjusting for frailty, aTIV showed statistically significantly better protection than naTIV against influenza-associated hospitalizations in older adults. In future studies, it is important to consider frailty as a significant confounder of VE.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Adjuvants, Immunologic / Influenza, Human / Frailty / Vaccine Efficacy Type of study: Screening_studies / Systematic_reviews Limits: Aged / Humans Country/Region as subject: America do norte Language: En Journal: Vaccine Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Adjuvants, Immunologic / Influenza, Human / Frailty / Vaccine Efficacy Type of study: Screening_studies / Systematic_reviews Limits: Aged / Humans Country/Region as subject: America do norte Language: En Journal: Vaccine Year: 2023 Document type: Article Affiliation country: